Vertex casually drops Orkambi revenue slowdown, creating

Cystic fibrosis drugmaker Vertex this week informally backed away from its revenue guidance for key med Orkambi--and investors should be just as unhappy with execs’ conduct as they should be about | Cystic fibrosis drugmaker Vertex this week informally backed away from its revenue guidance for key med Orkambi--and investors should be just as unhappy with execs’ conduct as they should be about the revenue slip, one analyst says.

SEC Filing – Royalty Pharma

Dropbox Business Model - How Dropbox Makes Money?

BART on X: Board Workshop started with Regional Context & Financial Outlook presented by staff followed by Board discussion. Downtown San Francisco has had the slowest recovery among peer Downtowns. BART ridership

Vertex casually drops Orkambi revenue slowdown, creating 'unnecessary drama' for investors

Vertex casually drops Orkambi revenue slowdown, creating 'unnecessary drama' for investors

Security Solutions Today: Jul-Aug 2020 by Security Solutions Today - Issuu

What competition? Vertex touts Trikafta's competitive edge on back of strong 2021

Oracle Stock (ORCL) Jumps After Revenue Tops Estimates on Strong Cloud Effort - Bloomberg

Dropbox Stock: Slowing Growth? So What! (NASDAQ:DBX)

S-1

SEC Filing – Royalty Pharma

What Investors Need to Know About Oracle's Cloud Slowdown

S-1/A